NCT06238908View on ClinicalTrials.gov

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2030

Conditions
Hemophilia A
Interventions
DRUG

NGGT003

Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER